An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients
Phase of Trial: Phase IV
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Canakinumab (Primary)
- Indications Cryopyrin-associated periodic syndromes
- Focus Adverse reactions
- Acronyms B-Confident
- Sponsors Novartis
- 17 Jun 2017 Results (n=68) presented at the 18th Annual Congress of the European League Against Rheumatism.
- 11 Jun 2016 Final results reporting safety and efficacy from the Beta-Confident Registry presented at the 17th Annual Congress of the European League Against Rheumatism.
- 25 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.